The state of biotech M&A 2024

This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.

Biotech M&A has been disappointing. Perhaps the trend will improve before we reach the holidays, but I can only opine on what’s transpired, and honestly, that’s not much.

By my count, there have been 35 transactions totaling $45 billion. My M&A list might differ from others, but I tried to capture all the meaningful activity, year to date.

STAT+ Exclusive Story

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Are back problems influenced by your gut?

Findings suggest gut microbiome dysbiosis may influence lumbar degenerative spondylolisthesis, impacting inflammation and pain management strategies.

October 25, 2024

SLU research finds link between anxiety disorders, benzodiazepine exposure and dementia in seniors

Research from Saint Louis University School of Medicine finds that among patients 65 and older, a diagnosis of anxiety was significantly associated with an increased

August 8, 2023

Oregon suspends a portion of its drug transparency law found to be unconstitutional

In a victory for the pharmaceutical industry, Oregon officials have suspended a portion of a contentious state law designed to bring more transparency to prescription

February 23, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.